Reviewer’s report

**Title:** A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries

**Version:** 0  **Date:** 05 Nov 2017

**Reviewer:** Roberta Lanzillo

**Reviewer's report:**

This is an interesting trial with DMF performed in Asian ethnicity RRMS patients, due to the epidemiological and pathological differences between white and Asian origin MS patients. The results are mainly in line with registration trials, but this study was focused only on enhancing lesions at brain MRI, being under-powered to assess any clinical differences, therefore I think that the authors should better discuss the role of MRI as a surrogate marker of disease in trials.

Moreover, since MRI was the primary endpoint, MRI methodology should be described.

Regarding the efficacy of DMF, in line with recent literature, it would be interesting if the authors could emphasize NEDA results in this small and short term trial, as pointed in recent papers (see Havdrova E, and Lanzillo R, Eur J Neurol 2017)

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I served as consultant in advisory boards for Biogen, Merck, Novartis, Teva, Genzyme.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.